口服抗凝药用于设备检测心房颤动患者卒中预防的Meta分析
结果显示,艾多沙班或阿哌沙班抗凝可显著降低缺血性卒中风险(RR 0.68),但增加大出血风险(RR 1.62),对死亡率无显著影响。
要点
- 设备检测房颤患者口服抗凝可降低缺血性卒中风险(RR 0.68)。
- 抗凝治疗增加大出血风险(RR 1.62),需个体化权衡。
- 对心血管死亡和全因死亡无显著改善。
核心结论
- 口服抗凝药(艾多沙班或阿哌沙班)可降低设备检测房颤患者的缺血性卒中风险,但增加大出血风险。
主要发现
- 口服抗凝降低缺血性卒中风险(RR 0.68,95%CI 0.50-0.92,高质量证据,I²=0%)。
- 口服抗凝降低心血管死亡、全因卒中、外周动脉栓塞、心肌梗死或肺栓塞复合终点(RR 0.85,95%CI 0.73-0.99,中等质量证据,I²=0%)。
- 口服抗凝未降低心血管死亡(RR 0.95,95%CI 0.76-1.17,中等质量证据,I²=0%)或全因死亡(RR 1.08,95%CI 0.96-1.21,中等质量证据,I²=0%)。
- 口服抗凝增加大出血风险(RR 1.62,95%CI 1.05-2.50,高质量证据,I²=61%)。
临床怎么用
- 对于设备检测房颤患者,可考虑使用艾多沙班或阿哌沙班抗凝以降低缺血性卒中风险,但需充分评估出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Device-detected atrial fibrillation (also known as subclinical atrial fibrillation or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Whether oral anticoagulation is effective and safe in this patient population is unclear. METHODS: We performed a systematic review of MEDLINE and Embase for randomized trials comparing oral anticoagulation with antiplatelet or no antithrombotic therapy in adults with device-detected atrial fibrillation recorded by a pacemaker, implantable cardioverter defibrillator, cardiac resynchronization therapy device, or implanted cardiac monitor. We used random-effects models for meta-analysis and rated the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework (GRADE). The review was preregistered (PROSPERO CRD42023463212). RESULTS: From 785 citations, we identified 2 randomized trials with relevant clinical outcome data: NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes; 2536 participants) evaluated edoxaban, and ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; 4012 participants) evaluated apixaban. Meta-analysis demonstrated that oral anticoagulation with these agents reduced ischemic stroke (relative risk [RR], 0.68 [95% CI, 0.50-0.92]; high-quality evidence). The results from the 2 trials were consistent (I2 statistic for heterogeneity=0%). Oral anticoagulation also reduced a composite of cardiovascular death, all-cause stroke, peripheral arterial embolism, myocardial infarction, or pulmonary embolism (RR, 0.85 [95% CI, 0.73-0.99]; I2=0%; moderate-quality evidence). There was no reduction in cardiovascular death (RR, 0.95 [95% CI, 0.76-1.17]; I2=0%; moderate-quality evidence) or all-cause mortality (RR, 1.08 [95% CI, 0.96-1.21]; I2=0%; moderate-quality evidence). Oral anticoagulation increased major bleeding (RR, 1.62 [95% CI, 1.05-2.50]; I²=61%; high-quality evidence). CONCLUSIONS: The results of the NOAH-AFNET 6 and ARTESiA trials are consistent with each other. Meta-analysis of these 2 large randomized trials provides high-quality evidence that oral anticoagulation with edoxaban or apixaban reduces the risk of stroke in patients with device-detected atrial fibrillation and increases the risk of major bleeding.
引用
- McIntyre, Benz, Becher, et al. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation. 2023. PMID: 37952187. doi:10.1161/CIRCULATIONAHA.123.067512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。